Discontinue use if sudden vision defect, decreased or hearing loss occur. Increased risk of NAION. Anatomical penis deformation (eg, angulation, cavernosal fibrosis or Peyronie's disease) or conditions predisposing to priapism eg, sickle cell anaemia, multiple myeloma or leukemia. Serious CV events eg, MI, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations & tachycardia. Assess CV status prior to treatment; patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy. Not to be used in combination w/ other PDE5 inhibitors or other treatments for erectile dysfunction. Not recommended in combination w/ doxazosin. Concomitant use w/ α1
-blockers, potent CYP3A4 inhibitors eg, ritonavir, saquinavir, ketoconazole, itraconazole, erythromycin. Not to be used in galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Severe hepatic insufficiency (Child-Pugh class C). Not to be used in women. Avoid use during pregnancy. Not to be used during lactation.